Literature and evidence database
Find the source, the model and the boundary.
Search source records connected to the product-family knowledge base. Filter by category, product, publication year, research type, study model and editorial evidence tier.
Product evidence maps
A focused source set for each product.
Search and filter
Evidence records
Narrow the records by product, year or study model. Open each source to check its results and limitations.
L-Carnitine Supplementation in Recovery after Exercise
Fielding R, et al. Nutrients. 2018. PMID 29534031.
Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice
Neelakantan H, et al. Biochemical Pharmacology. 2018;147:141–152. PMID 29155147 · DOI 10.1016/j.bcp.2017.11.007
Small-molecule inhibitors of nicotinamide N-methyltransferase
J. Med. Chem. 2017. PMID 28548833 · DOI 10.1021/acs.jmedchem.7b00389.
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis
Lee C, et al. Cell Metabolism. 2015. PMID 25738453.
Comparative study of nanoparticle-targeted therapeutics and bioconjugates
Daquinag AC, et al. Molecular Pharmaceutics. 2013. PMID 23871959.
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys
Barnhart KF, et al. Science Translational Medicine. 2011. PMID 22072637.
AOD-9604 development review
Wilding J. Current Opinion in Investigational Drugs. 2004. PMID 15134286.
Certain Bulk Drug Substances That May Present Significant Safety Risks
U.S. FDA. Current compounding safety-information page.
A Study of Retatrutide in Participants Who Have Obesity or Overweight
ClinicalTrials.gov record NCT04881760.
SYNCHRONIZE-1 trial registry
ClinicalTrials.gov NCT06066515.
ZEPBOUND (tirzepatide) prescribing information
U.S. Food and Drug Administration. Current Drugs@FDA label for NDA 217806.
Investigation of Safety and Efficacy of Cagrilintide
ClinicalTrials.gov record NCT03856047.
Care and handling of peptides
Care and handling of peptides
Tirzepatide for Obesity Treatment and Diabetes Prevention.
Tirzepatide for Obesity Treatment and Diabetes Prevention.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction.
Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction.
Peptide Isolation – Method Development Considerations
Peptide Isolation – Method Development Considerations
Humanin peptide suppresses apoptosis by interfering with Bax activation
Humanin peptide suppresses apoptosis by interfering with Bax activation
Humanin induces conformational changes in the apoptosis regulator BAX and sequesters it into fibers, preventing mitochondrial outer-membrane permeabilization
Humanin induces conformational changes in the apoptosis regulator BAX and sequesters it into fibers, preventing mitochondrial outer-membrane permeabilization
Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells
Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells
Analyzing Kinetic Binding Data
Analyzing Kinetic Binding Data
Receptor Binding Assays for HTS and Drug Discovery
Receptor Binding Assays for HTS and Drug Discovery
Solubility Guidelines for Peptides
Solubility Guidelines for Peptides
Retatrutide interactions with three receptors
Retatrutide interactions with three receptors
PDB 8YW3: Retatrutide–GLP-1R–Gs structure
PDB 8YW3: Retatrutide–GLP-1R–Gs structure
PDB 8YW4: Retatrutide–GIPR–Gs structure
PDB 8YW4: Retatrutide–GIPR–Gs structure
PDB 8YW5: Retatrutide–GCGR–Gs structure
PDB 8YW5: Retatrutide–GCGR–Gs structure
Editorial methodology
How records are classified
Records are deduplicated by source URL and linked to every relevant product family. Study type and model are inferred from the citation and editorial evidence label, then reviewed during content QA.
Read the full editorial, AI-assistance and correction policy →
Labels and databases supporting regulatory status, formulation or chemical identity.
Controlled trials, systematic reviews and other clinical records with population-specific interpretation.
Animal, cell, analytical and mechanistic records that cannot establish human outcomes.
Narrative reviews, registries and sponsor reports kept visibly distinct from peer-reviewed outcomes.
Use the records
